NCT04073550 - Study of Anlotinib Hydrochloride Capsule in Subjects With Small Cell Lung Cancer | Biotech Hunter

Enrollment

184

Participants

Timeline

Start Date

October 31, 2019

Primary Completion Date

July 31, 2021

Study Completion Date

July 31, 2022

Conditions

Small Cell Lung Cancer

Interventions

DRUG

Anlotinib

A multi-target receptor tyrosine kinase inhibitor.

DRUG

Placebos

Anlotinib blank analog capsule.

DRUG

Topotecan

A topoisomerase I inhibitor.

Trial Locations (2)

Beijing Cancer Hospital, Beijing

Cancer Hospital Chinese Academy of Medical Sciences, Beijing